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SOX10 Promotes Melanoma Cell Invasion by
Regulating Melanoma Inhibitory Activity
Saskia A. Graf1, Christian Busch2, Anja-Katrin Bosserhoff3, Robert Besch1,4 and Carola Berking1,4
The transcription factor SOX10 (SRY (sex determining region Y)-box 10) has a key role in the embryonic
development of melanocytes. Recently, it has been suggested that SOX10 is highly relevant for melanoma
development and survival. However, the distinct functions and downstream targets of SOX10 in melanoma remain
widely unknown. In this study, we inhibited SOX10 via RNA interference in different human melanoma cell lines
and found a significantly reduced invasion capacity in vitro and in the chick embryo model. At later time points,
SOX10 inhibition reduced proliferation and induced cell death. We identified melanoma inhibitory activity (MIA)
as a direct target gene of SOX10, which is an essential protein for melanoma cell migration and invasion.
Expression levels of SOX10 and MIA strictly correlated in melanoma cell lines, and SOX10 inhibition reduced MIA
expression and promoter activity. Direct binding of SOX10 to the MIA promoter was demonstrated by
electrophoretic mobility shift assay and chromatin immunoprecipitation. Ectopic expression of MIA in SOX10-
inhibited melanoma cells restored the invasion capacity, supporting the hypothesis that MIA is responsible for
SOX10-mediated melanoma cell invasion. Our data provide evidence for a critical role of SOX10 in melanoma cell
invasion through the regulation of MIA and highlight its role as a therapeutic target in melanoma.
Journal of Investigative Dermatology (2014) 134, 2212–2220; doi:10.1038/jid.2014.128; published online 10 April 2014
INTRODUCTION
Melanoma is the most lethal form of skin cancer. Despite the
introduction of targeted therapy against mutated BRAF with
unprecedented response rates, melanoma treatment remains a
challenge because of the common development of therapy
resistance. Therefore, the identification of alternative thera-
peutic targets is of high interest.
The high-mobility group domain transcription factor SOX10
(SRY (sex determining region Y)-box 10) is a key molecule in
the embryonic development of melanocytes. SOX10 expres-
sion is initiated in premigratory neural crest cells and controls
multipotency, survival, and proliferation of neural crest cells
as well as their differentiation into peripheral glial cells and
pigment cells at later stages (Harris et al., 2010). Homozygous
deletion of SOX10 in mice leads to embryonic lethality,
whereas SOX10 haploinsuffiency causes aganglionosis of the
colon and pigmentation defects (Herbarth et al., 1998). During
differentiation into the melanocyte lineage, SOX10 activates
microphthalmia-associated transcription factor (Bondurand
et al., 2000; Dutton et al., 2001) and melanogenic enzymes
such as dopachrome tautomerase and tyrosinase (Potterf et al.,
2001; Ludwig et al., 2004; Murisier et al., 2007).
Along with others, we have shown SOX10 expression in
primary and metastatic melanoma (Agnarsdo´ttir et al., 2010;
Bakos et al,. 2010; Shakhova et al., 2012). Previous studies
revealed low frequencies of intragenic mutations in the
SOX10 gene, suggesting that maintenance of SOX10 wild-
type function is required for melanoma formation and
maintenance (Cronin et al., 2009, 2013). Recently, a critical
role for SOX10 in melanomagenesis has been demonstrated in
different mouse models (Shakhova et al., 2012; Cronin et al.,
2013). Moreover, SOX10 seems to be important for melanoma
cell proliferation and survival. However, the molecular
mechanisms concerning how SOX10 exerts its effects remain
unclear.
In this study, the role of SOX10 was investigated in
different human melanoma cell lines. Inhibition studies
revealed a critical role of SOX10 in melanoma cell invasion
and survival. Furthermore, we identified melanoma inhibitory
activity (MIA) as a new target gene of SOX10 in melanoma,
which seems to be responsible for the invasion-promoting role
of SOX10.
RESULTS
Expression of SOX10 in human skin and melanoma cells
SOX10 expression was analyzed by quantitative real-time
PCR (Figure 1a) and immunoblotting (Figure 1b) in human
fibroblasts, melanocytes, and 12 melanoma cell lines of
different progression stages. SOX10 was highly expressed in
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melanocytes on messenger RNA level (Figure 1a), whereas it
was less pronounced on protein level (Figure 1b). SOX10
messenger RNA amounts varied among melanoma cell lines
and did not correlate with progression stage (Figure 1a).
SOX10 protein was detected in 8 of 12 melanoma cell lines,
whereas 2 of the 4 negative ones were of the radial growth
phase subtype, suggesting that SOX10 protein levels are
associated with a more invasive or metastatic phenotype
(Figure 1b). In fibroblasts, SOX10 messenger RNA levels were
low and no SOX10 protein was observed (Figure 1a and b).
SOX10 inhibition leads to cell death in melanoma cells
SOX10 was inhibited in melanoma cell lines via RNA
interference. Two different small interfering RNAs (siRNAs;
siSOX10a and siSOX10b) were used in order to control
nonspecific effects and tested in three different melanoma cell
lines. Both siRNAs efficiently inhibited SOX10 in all cell lines
as early as 24 hours after siRNA transfection (Figure 2a).
Microscopic evaluation revealed increased cell detachment
72 hours after SOX10 inhibition and a reduced cell number
most prominent after 120 hours, suggesting the onset of cell
death (Figure 2b). Apoptotic and dead cells were quantified by
FACS after staining with Annexin V and propidium iodide
(Figure 2c and d). Cell death was significantly increased
72 hours after SOX10 inhibition, with a distinct increase in
the apoptotic sub-population of up to 6% in 1205Lu
(Figure 2c). Time course quantifications after SOX10 inhibition
revealed a significant reduction of viable cells by 10–30%
after 72 hours and by 30–60% after 120 hours (Figure 2d and
Supplementary Figure S1b online). Cleavage of caspase 3 was
detected by immunoblotting 120 hours after siRNA transfec-
tion, with a slightly stronger effect of siSOX10a compared with
that of siSOX10b (Supplementary Figure S1a online). Cell
cycle analysis of 1205Lu revealed that cell death was
preceded by cell cycle arrest in G1 phase after 48 hours
(Supplementary Figure S2c online). Taken together, SOX10 is
important for melanoma cell survival and proliferation.
SOX10 promotes melanoma cell invasion
SOX10 is expressed in neural crest cells and melanoblasts
during migration along the dorso-lateral pathway (Southard-
Smith et al., 1998). We therefore hypothesized that SOX10
influences melanoma cell migration and invasion. The
invasion capacity of different SOX10-inhibited melanoma
cell lines was significantly reduced as assessed by Matrigel
assay (Figure 3a) as well as by an embryonic chick model
(Figure 3b–h). 1205Lu melanoma cells were injected into the
rhombencephalic brain vesicle of chick embryos at an early
embryonic stage (Busch et al., 2012). Ninety-six hours later,
histological analysis revealed melanoma nodules with a
central necrotic area in all embryos in the midline of the
roof plate, the adjacent mesenchymal tissues, and the surface
ectoderm after injection of either SOX10-inhibited (siSOX10a),
control siRNA-treated (siControl), or untreated (no siRNA)
1205Lu cells (Figure 3b). More than 90% of the tumor cells
stained positive for the proliferation marker mindbomb E3
ubiquitin protein ligase 1 (Figure 3c) and the nodules did not
differ in size between experimental groups (Figure 3d). This
was also true for the tumors formed by SOX10-inhibited cells,
suggesting that cell proliferation was not affected in this
experimental setting. However, SOX10-inhibited melanoma
cells showed a significantly reduced number of invading cells
compared with controls in which invasion of both single and
clusters of melanoma cells into the surrounding mesenchymal
host tissue was evident (Figure 3e). SOX10 staining revealed
strong nuclear signals in the nodules and invading tumor cells
(Figure 3f and g), whereas SOX10 staining was absent or
reduced in the tumors formed by SOX10-inhibited melanoma
cells (Figure 3h). These data suggest that SOX10 has a critical
role in melanoma cell invasion independent from cell
proliferation.
SOX10 regulates MIA
As MIA has been extensively described to be essential for
melanoma cell migration and invasion (Schmidt et al., 2013)
and has been shown to be regulated by SOX9, a SOX10-
related transcription factor in cartilage cells (Xie et al., 1999),
we wondered whether SOX10 was associated with MIA in
melanoma cells.
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Figure 1. Expression of SOX10 in human skin cells and melanoma cell lines.
(a) SOX10 mRNA (mean±SD) was assessed by quantitative real-time PCR in
fibroblasts (two donors, white bars), melanocytes (three donors, black bars),
and melanoma cell lines of different progression stages (gray bars). (b) SOX10
protein expression was assessed in the same cells as described in (a). b-Actin
served as a loading control. mRNA, messenger RNA; RGP, radial growth
phase; SOX10, SRY (sex determining region Y)-box 10; VGP, vertical growth
phase.
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MIA expression was analyzed in fibroblasts, melanocytes,
and melanoma cells by quantitative real-time PCR and
immunoblotting (Figure 4a). Confirming previously published
data (Bosserhoff et al., 1996; Perez et al., 2000), MIA was
expressed in the majority (8 of 12) of melanoma cell lines,
although it was absent in fibroblasts and melanocytes. No
mutations of SOX10 and MIA were found in WM278,
WM1232, and 1205Lu, except for a silent mutation of
SOX10 in 1205Lu melanoma cells (data not shown). In all
investigated cell lines, MIA correlated with SOX10, but not
with SOX9 expression (Figure 4a–c). Notably, MIA was absent
in melanocytes displaying high levels of SOX10. As CtBP1 had
been described as a repressor of MIA with strong expression in
melanocytes as opposed to melanoma (Poser et al., 2002), we
have analyzed CtBP1 and indeed found an increased
expression in melanocytes compared with melanoma cells
(Supplementary Figure S2a online). Other previously pub-
lished activators of MIA, i.e., high-mobility group 1 and p65,
did not correlate with MIA expression, thereby strengthening
the crucial role of SOX10 in MIA regulation (Supplementary
Figure S2b online).
Next, MIA expression was analyzed in SOX10-inhibited
cells. Transfection of SOX10-targeting siRNAs strongly reduced
MIA expression in all three examined melanoma cell
lines (Figure 5a). To check for possible cross-reactivity,
SOX9 expression was analyzed but did not reveal significant
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Figure 2. SOX10 inhibition induces cell death in melanoma cells. (a) SOX10 silencing was assessed by immunoblotting 24 hours after treatment with two
different SOX10-targeting siRNAs (siSOX10a and siSOX10b) compared with control siRNA (siControl) in three melanoma cell lines. (b) Microscopic evaluation
of 1205Lu cells upon SOX10 inhibition 24, 72, and 120 hours after siRNA treatment (scale bar¼100mm). (c) Dot plots of FACS data are representative for
siSOX10a- and siControl-treated 1205Lu cells 24 and 72 hours after transfection. Values in the quadrants represent quantification of AN–PIþ (upper left),
ANþ PIþ (upper right), and ANþ PI– (lower right) cells. (d) Cell death of melanoma cells was assessed by AN and PI staining and FACS quantification 24, 48, 72,
96, and 120 hours after transfection with siSOX10a, siSOX10b, siControl, or without siRNA (mean±SD; one-way ANOVA vs. siControl, *Po0.05). AN, Annexin
V; ANOVA, analysis of variance; PI, propidium iodide; siRNA, small interfering RNA; SOX10, SRY (sex determining region Y)-box 10.
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changes, confirming specificity of the siRNAs used (data not
shown).
To evaluate the effect of SOX10 inhibition on MIA promoter
activity, we performed luciferase assays with a MIA promoter
construct (Figure 5b). SOX10 inhibition almost abolished the
activity of the MIA reporter. To assess SOX10 binding in the
MIA promoter, chromatin immunoprecipitation was per-
formed in 1205Lu melanoma cells (Figure 5c). SOX10 binding
in the MIA promoter was increased around 4-fold compared
with control genomic DNA or control IgG. We further
determined the SOX10-responsive promoter elements by using
truncated versions of the MIA promoter (Figure 5d). Truncated
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Figure 3. SOX10 inhibition impedes melanoma cell invasion. (a) WM278, WM1232, and 1205Lu melanoma cells were subjected to Matrigel invasion assay.
SOX10 inhibition significantly reduced the number of invaded melanoma cells in three independent experiments (one-way ANOVA vs. siControl, *Po0.05).
(b) 1205Lu melanoma cells were injected into the rhombencephalic brain vesicle of chick embryos after transfection with siSOX10a, siControl, or without siRNA.
Tumor formation and invasion were analyzed 96hours later. Representative chick embryo sections were stained with H&E (b, scale bar¼ 100mm), anti–mindbomb
E3 ubiquitin protein ligase 1 (c, scale bar¼ 50mm), or anti-SOX10 antibodies (f, scale bar¼100mm; g, h, scale bar¼ 20mm). Arrows show invading melanoma
cells. (d) Maximum diameter of each tumor was measured microscopically in two directions. NS (P40.05). (e) Quantity of invading cells was assessed by counting
three sections of the largest tumor diameter of each embryo (siSOX10a n¼ 6, siControl n¼ 4, no siRNA n¼ 7; one-way ANOVA vs. siControl, *Po0.001).
ANOVA, analysis of variance; H&E, hematoxylin and eosin; NS, not significant; siRNA, small interfering RNA; SOX10, SRY (sex determining region Y)-box 10.
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promoter fragments 200- and 212-bp upstream of the tran-
scription start site displayed SOX10 responsiveness, while it
was increased in longer constructs (493 and 275 bp) and
lost in the 160-bp fragment. In silico analysis of the SOX10-
responsive part of the MIA promoter revealed five potential
SOX binding sites (#1–#5; Figure 5e). Each candidate binding
site was mutated and tested for its promoter activity. Mutation
of sites #4 and #5 led to an almost complete loss of MIA full-
length promoter activity, indicating that these sites are critical
for MIA expression. Furthermore, SOX10 binding to the
predicted binding sites in the MIA promoter was tested in
electrophoretic mobility shift assays with a DNA probe repre-
senting a MIA promoter fragment that contains both binding
sites (#4 and #5), which are in close vicinity. A published SOX
consensus sequence (Cook et al., 2005) served as positive
control. Shift patterns of the MIA promoter fragment compared
with the positive control suggested multimeric binding of
SOX10 to this MIA promoter region (Figure 5f, lanes 1 and 4).
In conclusion, MIA is a newly identified, direct target gene
of SOX10 in melanoma and may be the mediator of the pro-
invasive effects of SOX10.
MIA mediates reduced invasion upon SOX10 inhibition
We next tested whether downregulation of MIA in SOX10-
inhibited cells is indeed responsible for reduced melanoma
cell invasion. MIA was ectopically expressed in 1205Lu
melanoma cells in the presence of SOX10 inhibition and
invasion was assessed in Matrigel assays (Figure 6a and b). As
seen before, SOX10 inhibition strongly reduced Matrigel
invasion, which was not affected by co-transfection of a
control vector. In contrast, expression of MIA almost com-
pletely restored the invasive capability of SOX10-inhibited
1205Lu cells, although it did not significantly alter invasion of
control cells. Thus, MIA seems to be critical for SOX10-
mediated melanoma cell invasion.
DISCUSSION
In this study, we found high SOX10 expression in melanocytes
as well as in most melanoma cell lines. By inhibiting SOX10
in different melanoma cell lines, we identified SOX10 as a
critical factor for melanoma cell invasion. Our data also
confirm the previously described role of SOX10 for melanoma
cell survival at later time points (Shakhova et al., 2012; Cronin
et al., 2013). Mechanistically, we identified MIA as a direct
target gene of SOX10, which seems to mediate the pro-
invasive function of SOX10 in melanoma.
SOX10 has been established as a sensitive marker for
melanocytic lesions, with positive staining in nevi and mela-
noma (Nonaka et al., 2008; Mohamed et al., 2012). Broad
SOX10 expression with varying protein levels in melanoma
cell lines has been described before (Flammiger et al., 2009;
Mascarenhas et al., 2010). In this study, SOX10 expression
levels were higher in melanocytes than in melanoma cell
lines. In contrast, Cook et al. (2005) demonstrated less SOX10
expression in melanocytes compared with melanoma cells,
although it was upregulated in melanoblasts. Different cell
culture conditions as well as different melanocyte donors may
cause these discrepancies. According to our in vitro messenger
RNA data, Agnarsdottir et al. (2010) observed stronger nuclear
staining of SOX10 in normal melanocytes and benign nevi
compared with melanoma samples in situ. In situ data from
our group and others showed more common SOX10 staining
in primary and metastatic melanoma compared with
melanocytic nevi (Bakos et al., 2010, Mascarenhas et al.,
2010). Other groups found strong nuclear SOX10 staining in
all primary and most metastatic melanoma tissue samples
(Nonaka et al., 2008; Shakhova et al., 2012). Strong SOX10
expression in melanoma tissues correlated with poor
prognosis (Agnarsdo´ttir et al., 2010; Civenni et al., 2011).
The varying SOX10 expression data in melanocytes and
melanoma cells may be due to different culture conditions
in vitro and different antibodies in situ. Nevertheless, our data
confirm that SOX10 is a marker of the melanocytic lineage
and commonly expressed in melanoma.
The association of SOX10 with melanoma cell proliferation
and survival has been described earlier (Shakhova et al., 2012;
Cronin et al., 2013). Shakhova et al. (2012) demonstrated that
SOX10 inhibition via short hairpin RNA resulted in cell cycle
arrest followed by apoptosis with similar kinetics as in our
experiments. In contrast, Cronin et al. (2013) observed sene-
scence without induction of apoptosis 1 week after SOX10
inhibition via short hairpin RNA in different cell lines.
However, no senescence could be detected 72 hours after
transfection with siRNA. Despite these differing results, which
may be attributed to heterogeneity in melanoma cell lines, all
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Figure 4. MIA correlates with SOX10 expression in melanoma cells. (a) MIA
and SOX9 expression was assessed by immunoblotting in fibroblasts (two
donors), melanocytes (three donors), and melanoma cell lines. SOX10
immunoblot of Figure 1b is shown for better comparison. (b) Positive linear
correlation between SOX10 and MIA mRNA, determined by quantitative real-
time PCR (Pearson coefficient 0.6293, Po0.05). (c) No significant correlation
between SOX9 and MIA mRNA (Pearson coefficient –0.1594, P40.05). MIA,
melanoma inhibitory activity; mRNA, messenger RNA; SOX10, SRY (sex
determining region Y)-box 10.
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data highlight a pivotal role of SOX10 in melanoma cell
survival at advanced time points after SOX10 knockdown.
The influence of SOX10 on melanoma cell migration has
been suggested previously. Migration assays have been per-
formed as transwell assays against a nutrition gradient
(Agnarsdo´ttir et al., 2010) or conditioned medium (Seong
et al., 2012). Although Agnarsdo´ttir et al. (2010) found both an
increased (WM793) and a decreased (WM115) melanoma cell
migration capacity upon SOX10 inhibition via siRNA, Seong
et al. (2012) demonstrated a 75% decrease in migration in
murine B16 melanoma cells. The latter is in accordance with
our findings that SOX10-inhibited human melanoma cell lines
had a decreased invasive capacity of up to 75%. Reduced
invasiveness into the surrounding host tissue was also seen in
a chick embryo model, although tumor sizes and proliferative
activity did not differ between SOX10-inhibited and control
melanoma cells. This sustained survival as opposed to the
in vitro data may be caused by the chick microenvironment,
with embryonic growth factors counteracting apoptosis and
cell cycle arrest. Furthermore, the onset of impaired cell
invasion occurred at an earlier time point than the onset of
increased cell death after SOX10 inhibition in vitro.
Reduced migration in B16 melanoma cells had been attri-
buted to known SOX10 target genes, such as microphthalmia-
associated transcription factor or melanocortin 1 receptor,
without further validation (Seong et al., 2012). In this study,
we could relate reduced invasion of SOX10-inhibited
melanoma cells to MIA, a key molecule for melanoma
migration and invasion. As MIA overexpression in SOX10-
inhibited melanoma cells did not completely restore their
invasion capacity, we cannot exclude the involvement of
further SOX10 target genes.
MIA is an established melanoma marker and correlates
with melanoma progression in vivo, although it is absent in
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Figure 5. MIA is a direct target gene of SOX10 in melanoma. (a) SOX10 and MIA expression was assessed by immunoblotting 24 and 72 hours after
transfection with siSOX10a, siSOX10b, or siControl in three melanoma cell lines. (b) MIA full-length promoter activity (mean±SD) was determined by luciferase
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DIG, digoxigenin; EMSA, electrophoretic mobility shift assay; MIA, melanoma inhibitory activity; SOX10, SRY (sex determining region Y)-box 10.
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melanocytes (Bosserhoff et al., 1997a; Perez et al., 2000). On
a cellular level, MIA is secreted at the rear pole of migrating
melanoma cells and directly interacts with cell adhesion
receptors and extracellular matrix molecules promoting cell
migration and invasion (Schmidt et al., 2013). MIA, also
known as cartilage-derived retinoic acid–sensitive protein, is
not only crucial for melanoma cell migration but also for
chondrogenesis and is expressed throughout cartilage devel-
opment (Bosserhoff et al., 1997b; Schmid et al., 2010).
Another SOX transcription factor, SOX9, which is important
for chondrogenesis, was found to activate MIA in
chondrocytes (Xie et al., 1999). However, MIA seems to be
specifically activated by SOX10 in melanoma. In contrast to
SOX9, MIA and SOX10 expression strictly correlated in all
examined melanoma cell lines and SOX10 inhibition reduced
MIA expression, as early as 24 hours after transfection of
SOX10-targeting siRNAs. Direct binding of SOX10 to a
specific MIA promoter region was shown by reporter and
chromatin immunoprecipitation assays. Moreover, we were
able to identify two SOX binding sequences, which are crucial
for MIA full-length promoter activity and seem to be bound by
SOX10 in a multimeric pattern. Interestingly, SOX9 was
demonstrated to activate the same SOX consensus site in the
cartilage-derived retinoic acid–sensitive protein promoter,
which is equivalent to the SOX10 binding site we identified
in the MIA promoter (binding site #5; Xie et al., 1999). When
comparing results of the promoter deletion constructs
(Figure 5d) with the mutation analyses (Figure 5e), it is obvious
that deletion constructs shorter than 275 bp retained SOX10
responsiveness, although potential SOX binding sites within
this area (sites #1–3) turned out to be not relevant for
MIA transcription. It is possible that other, yet unknown,
transcription factors regulated by SOX10 alter MIA expression
by binding to this area. As a consequence, SOX10 may
regulate MIA directly as well as indirectly by regulation of
factors that bind to the proximal promoter region. The
importance of MIA in mediating the pro-invasive effect of
SOX10 was demonstrated in a rescue experiment (Figure 6) in
which MIA overexpression in SOX10-inhibited melanoma
cells restored the invasion capacity of these cells. However,
invasion was not increased by MIA overexpression in control
cells with high endogenous MIA levels. It is likely that
extensive amounts of MIA may even reverse the pro-invasive
effects of MIA, possibly by inhibiting cell growth and adhesion
as shown previously upon exposure to exogenous MIA in vitro
(Blesch et al., 1994). Thus, we suggest that activation of MIA
by SOX10 is a crucial event in melanoma progression. As
SOX10 but not MIA is abundantly expressed in melanocytes,
additional factors may be involved in MIA activation.
CtBP1 has been shown to be a potent repressor of MIA with
increased CtBP1 expression in melanocytes and loss of
expression in melanoma (Poser et al., 2002). Similarly, we
found increased CtBP1 levels in melanocytes, although other
previously reported activators of MIA were not associated with
MIA in melanoma cells (Poser et al., 2003). Moreover,
epigenetic changes in melanocytes and melanoma cells may
have an impact on different regulation of MIA in these two
cell types.
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Figure 6. Ectopic MIA expression in SOX10-inhibited melanoma cells
increases invasion capacity. (a) 1205Lu cells were transfected with siSOX10a
(upper row), siSOX10b (middle row), or siControl (lower row) prior to
transfection with a MIA expression vector (pCMX-MIA; left panel) or a control
vector (pControl; right panel) and then subjected to the Matrigel invasion assay.
Representative inserts from five independent experiments are depicted. (b) The
number of invaded cells per insert after SOX10 inhibition was significantly
increased in pCMX-MIA-transfected 1205Lu cells compared with control
vector (n¼ 5, Student’s t-test, *Po0.05). Significant reduction of melanoma
cell invasion after SOX10 inhibition compared with control is shown (n¼ 5,
one-way ANOVA, **Po0.01). NS (P40.05). MIA, melanoma inhibitory
activity; NS, not significant; SOX10, SRY (sex determining region Y)-box 10.
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Although this study clearly shows an association between
SOX10 and invasion via the regulation of MIA, the role of
SOX10 in melanoma is most likely multifaceted.
SOX10 has been linked to the melanoma initiation factor
CD-271 and we have demonstrated previously that SOX10
together with SOX9 regulates the putative stem cell marker
nestin (Flammiger et al., 2009; Civenni et al., 2011). Tumor
formation of subcutaneously injected SOX10-inhibited mela-
noma cells in non-obese diabetic-severe combined immuno-
deficient and nude mice was impaired completely (Shakhova
et al., 2012). Cronin et al. (2013) suggested that reduced
tumor formation in mice that harbor SOX10 heterozygocity is
independent of its function as microphthalmia-associated
transcription factor activator. Interactions between melanoma-
genesis-related hypoxia-induced factor 2a and SOX10 have
been described in melanoma recently (Steunou et al., 2013).
All in all, SOX10 seems to be involved in melanoma initiation,
progression, and survival.
In summary, our study provides additional evidence that the
transcription factor SOX10 is active in melanoma and pro-
motes melanoma cell survival. Moreover, SOX10 affects
melanoma cell invasion via direct regulation of MIA. Thus,
SOX10 seems to represent a promising molecular target for
melanoma therapy affecting tumor growth and metastasis
formation.
MATERIALS AND METHODS
Cell culture
Human melanoma cell lines were a kind gift by Dr M Herlyn (Wistar
Institute, Philadelphia, PA) and cultivated as described in tumor 2%
medium (Hohenauer et al., 2013). Tissue origins of metastatic
melanoma cell lines were the lymph nodes (WM239a, WM9,
WM1158, and WM1232) and lungs (451Lu and 1205Lu). Primary
melanocytes and fibroblasts were isolated from human foreskins and
cultured as described before (Berking et al., 2001).
Quantification of viable cells and cell death
Before cell death analysis, viable cells were quantified in
six-well dishes by CellTiter-Blue cell viability assay (Promega,
Mannheim, Germany). For cell death quantification, adherent and
supernatant cells were stained with FITC-labeled Annexin V (Roche
Diagnostics, Mannheim, Germany) and propidium iodide (Sigma,
Taufkirchen, Germany). Annexin V staining was performed according
to the manufacturer’s instructions (Besch et al., 2009). Propidium
iodide was added to a final concentration of 0.5mg ml–1. Cells were
analyzed by flow cytometry and CellQuest software (Becton
Dickinson, Heidelberg, Germany).
Matrigel invasion assay
Invasion assays were performed using Matrigel-coated (39mg per
well; Becton Dickinson) 8mm pored ThinCert inserts in 24-well
plates (Greiner Bio-One, Frickenhausen, Germany). Twenty-four
hours after siRNA transfection, 150,000 cells were loaded on the
Matrigel-coated insert and allowed to invade toward fibroblast-
conditioned medium for 5 hours. Noninvasive cells were removed
and the remaining cells were fixed and stained with Diff-Quik
staining set (Medion Diagnostics, Duedingen, Switzerland). Invaded
cells were quantified by counting cells from whole inserts under the
microscope. Macroscopical pictures of stained inserts were taken
with a Canon G11 camera (Canon, Krefeld, Germany).
Chick embryo invasion assay
The chick embryo invasion assay was performed as recently
described in detail (Busch et al., 2013). Briefly, 1205Lu cells were
injected into the rhombencephalic brain vesicle of developing chick
embryos at stage 12 HH according to Hamburger and Hamilton
(1992). Embryos were incubated for further 96 hours at 38 1C before
fixation, paraffin embedding, and serial sectioning. For quantification
of melanoma cell invasion, the three middle sections with the largest
tumor diameters were analyzed in each embryo by counting the
invading mindbomb E3 ubiquitin protein ligase 1–positive melanoma
cells. The mean value represented the number of invading melanoma
cells per embryo. The maximum diameter of each tumor on the same
sections was measured in two dimensions using an Olympus BX51
microscope with a DP21 camera (Olympus, Hamburg, Germany).
Immunohistochemistry
The primary antibody for SOX10 staining of chick embryo sections
(polyclonal rabbit IgG, Medac Diagnostica, Wedel, Germany) was
used at a dilution of 1:25. Detection was performed with the alkaline
phosphatase anti-alkaline phosphatase method as described before
(Bakos et al., 2010). Hematoxylin and eosin staining and anti-
mindbomb E3 ubiquitin protein ligase 1 immunohistochemistry was
performed as previously described (Busch et al., 2013).
Statistical analysis
Unless otherwise stated, all experiments were performed in at least
three independent experiments. Data show mean values±SD. Statis-
tics were calculated in Prism v 5.04 (GraphPad Software, San Diego,
CA). Two groups were compared using the unpaired two-tailed
Student’s t-test. For multiple comparisons, one-way analysis of
variance with Dunnett’s post hoc test was used. Differences were
considered significant at a P-value of 0.05 or less.
Further methods
For siRNA and plasmid transfection, quantitative real-time PCR,
sequencing, immunoblotting, luciferase reporter assay, chromatin
immunoprecipitation, electrophoretic mobility shift assay, and cell
cycle analysis see Supplementary Material online.
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